subgroup, and gender (P¼0.007) was independent prognostic factor for OS in the EGFR mutation subgroup. Conclusion: This study confirmed the importance of pretreatment GNRI in predicting the OS in geriatric patients with metastatic lung adenocarcinoma, especially in the patients not harboring EGFR mutations. In the present research we had showed lnc-RNA HOTAIR is an optimal indicator of cell cycle disregulation in lung cancer. HOTAIR specific expression in lung primary tumor sample by the analysis of TCGA public database and 67 pairs of patients' tissues from our department. And through the TCGA public database KEGG analysis, HOTAIR is correlated with cell cycle pathway. Then we identified that HOTAIR and its 2 segments, HOTAIR3' and HOTAIR5', promote the cell cycle passing through the restriction point during G1-S phase by regulating Rb-E2Fs pathway and influence NSCLC cell proliferation, migration, and invasion through epithelial-mesenchymal transition (EMT) and b-catenin pathway in vitro and vivo. Last we had also showed the high expression of HOTAIR associated with fast resistance to gefitinb through dis-regulated cell cycle. Conclusion: In conclusion, HOTAIR could be an ideal indicator of cell cycle dysregulation and guide the use of cell cycle inhibitor. Burning Rock Biotech, Guangzhou/CN Background: ALK-rearranged NSCLC is a unique molecular subgroup with high sensitivity to ALK inhibitors. Crizotinib, a FDAapproved tyrosine kinase inhibitor for ALK-rearranged NSCLCs, showed remarkable response in ALK-positive NSCLC. However, the magnitude and duration of clinical responses to crizotinib among different ALK variants are found to be heterogeneous, and studies about the clinical outcomes showed contradict conclusions. Method: We collected sequencing information from 110 ALK-positive Chinese NSCLC patients, whose tissue or plasma biopsies were sequenced in a CLIA-certified genomic profiling laboratory. Sequencing results were reviewed with the intent of studying ALK rearrangement
Background: The dis-regulation of cell cycle is an obvious marker of tumors including lung cancer. Recently, the study of cell cycle inhibitor has made great progress in lung cancer. While a question, what kinds of patients could use cell cycle inhibitor, has plagued us. So seeking an accurate and convenient marker for the abnormal cell cycle in lung cancer is very important. Method: MTT, EdU, Transwell, ChIRP, Western-blot, luciferase reporter assay, Orthotopic nude mouse model, Immunohistochemistry. Results: In the present research we had showed lnc-RNA HOTAIR is an optimal indicator of cell cycle disregulation in lung cancer. HOTAIR specific expression in lung primary tumor sample by the analysis of TCGA public database and 67 pairs of patients' tissues from our department. And through the TCGA public database KEGG analysis, HOTAIR is correlated with cell cycle pathway. Then we identified that HOTAIR and its 2 segments, HOTAIR3' and HOTAIR5', promote the cell cycle passing through the restriction point during G1-S phase by regulating Rb-E2Fs pathway and influence NSCLC cell proliferation, migration, and invasion through epithelial-mesenchymal transition (EMT) and b-catenin pathway in vitro and vivo. Last we had also showed the high expression of HOTAIR associated with fast resistance to gefitinb through dis-regulated cell cycle. Conclusion: In conclusion, HOTAIR could be an ideal indicator of cell cycle dysregulation and guide the use of cell cycle inhibitor. Burning Rock Biotech, Guangzhou/CN Background: ALK-rearranged NSCLC is a unique molecular subgroup with high sensitivity to ALK inhibitors. Crizotinib, a FDAapproved tyrosine kinase inhibitor for ALK-rearranged NSCLCs, showed remarkable response in ALK-positive NSCLC. However, the magnitude and duration of clinical responses to crizotinib among different ALK variants are found to be heterogeneous, and studies about the clinical outcomes showed contradict conclusions. Method: We collected sequencing information from 110 ALK-positive Chinese NSCLC patients, whose tissue or plasma biopsies were sequenced in a CLIA-certified genomic profiling laboratory. Sequencing results were reviewed with the intent of studying ALK rearrangement distribution and clinical outcomes to crizotinib. Results: A total of 134 (5.6%) ALK rearrangements were identified in a cohort of 1971 NSCLCs, with 39 unique rearrangement partners. EML4 was the most common ALK rearrangement partner, with variant 3 (v3) as the most frequent variants (42.7%) of EML4-ALK fusion, accounting for 71.6% (96/134) of all the rearrangements in 87.3% (96/110) patients. For EML4-ALK positive patients after crizotinib treatment (n¼96), survival analysis revealed that patients with EML4-ALK only displayed favorable PFS (10.0 vs 7.2 months, p¼0.037) and OS (36.0 vs 20.0 months, p¼0.037) than those combined with other fusions. In vitro data reported that variant v3 and v5 was structurally stable and less sensitive to ALK inhibitors due to the lack of TAPE domain. In this study, patients harboring v3 and v5 displayed significantly inferior OS than those with other variants (31 vs 37.6 months, p¼0.010). For all the ALK-rearranged patients (n¼110), no significant difference was observed between the survival of EML4-ALK and non-EML4-ALK (PFS, 9.4 vs 14.5 months, p¼0.61; OS, 35.1 vs 35.5 months, p¼0.58), below and above 7.3 vs 11.3 months, p¼0.23; OS, 25.4 vs 35.5 months, p¼0.69) . Conclusion: This study demonstrated the distribution pattern of ALK rearrangements in Chinese NSCLCs, and illustrated the clinical outcomes of ALK-positive patients in different sub-groups. We hope this study could improve basic knowledge of ALK rearrangement and might be helpful for clinicians in choosing patients for appropriate medical treatment. Moreover, these findings advocate for more comprehensive ALK genomic profiling and validation of current results of clinical outcomes in large populations. Keywords: non-small cell lung cancers, ALK, Crizotinib
